%0 Journal Article %T Comparison of the effectiveness of different oral glucose lowering drugs in fasting patients with type II diabetes %J International Journal of Biomedicine and Public Health %I Negah Institute for Scientific Communication ( In Cooperation with Negah Scientific Publisher) %Z 2588-5375 %A Zakerkish, Mernoosh %A Shahbaziyan, Hajiyeh Bibi %A Karandish, Majid %A Rashidi, Homira %A Payami, Seyed Peyman %D 2018 %\ 04/27/2018 %V 1 %N 2 %P 59-66 %! Comparison of the effectiveness of different oral glucose lowering drugs in fasting patients with type II diabetes %K Hypoglycemia %K Metformin %K Repaglinide %K Sulfonylurea %K Type II diabetes %R 10.22631/ijbmph.2018.118140.1020 %X Introduction: Type 2 diabetes is the most common metabolic diseases in developed and developing countries with no effective treatment options. This study purpose was to compare different regimens of oral anti-diabetic therapy effects on the type 2 diabetic patients while fasting during Ramadan. Methods: In the double-blind controlled trial 90 patients with type 2 diabetes were divided randomly into three groups: 30 patients continued the previous dose of sulfonylurea (Group 1), 30 participants received a dose which was 25% lower than the previous sulfonylurea dose (group 2), and in the last 30 patients, repaglinide was replaced sulfonylurea (Group 3). Glucose, glycosylated hemoglobin (HbA1C), fructosamine, total cholesterol, low-density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides levels were measured in all participants before and after Ramadan. The weight and BMI were also controlled. Results: In all intervention groups a significant decreasing was seen in the body weight, BMI, fructoseamine, total cholesterol, and LDL; and also, a significant increasing was seen in HDL. The hypoglycemia incidence was significantly lower in Group 3 than Group 1. The results in fructosamine reduction and HDL cholesterol increasing were significantly better in Group 3 compared to Group 2 (P<0.05). Significant changes were not seen in total cholesterol, LDL, triglyceride, FBS, and HbA1C levels among the three treatment groups during Ramadan. Conclusion: The repaglinide consumption in comparing with sulfonylurea in patients with diabetes during Ramadan can cause fewer hypoglycemia, and better glycemic, and lipid control. %U https://www.ijbmph.com/article_61057_e131a1a08e565475e7922137717c538a.pdf